Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 144,871,840
  • Shares Outstanding, K 5,685,708
  • Annual Sales, $ 63,627 M
  • Annual Income, $ 8,031 M
  • EBIT $ 18,723 M
  • EBITDA $ 25,736 M
  • 60-Month Beta 0.47
  • Price/Sales 2.32
  • Price/Cash Flow 5.84
  • Price/Book 1.56

Options Overview Details

View History
  • Implied Volatility 25.31% (-0.70%)
  • Historical Volatility 18.93%
  • IV Percentile 49%
  • IV Rank 20.82%
  • IV High 52.17% on 04/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 4) 0.45 (1.78%)
  • Put/Call Vol Ratio 0.35
  • Today's Volume 158,230
  • Volume Avg (30-Day) 151,074
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 3,198,737
  • Open Int (30-Day) 3,162,268
  • Expected Range 24.82 to 25.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.58
  • Number of Estimates 5
  • High Estimate 0.68
  • Low Estimate 0.49
  • Prior Year 0.63
  • Growth Rate Est. (year over year) -7.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.83 +1.77%
on 01/02/26
26.65 -5.18%
on 12/15/25
-0.58 (-2.24%)
since 12/12/25
3-Month
23.91 +5.69%
on 11/10/25
26.65 -5.18%
on 12/15/25
+0.49 (+1.98%)
since 10/10/25
52-Week
20.92 +20.82%
on 04/09/25
27.69 -8.74%
on 10/03/25
-1.45 (-5.43%)
since 01/10/25

Most Recent Stories

More News
This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

CVS : 80.36 (+0.07%)
VHT : 292.57 (-0.14%)
NVO : 59.86 (+1.79%)
JNJ : 209.72 (+2.61%)
MRK : 109.19 (-1.21%)
HCA : 474.32 (+0.48%)
ABBV : 220.04 (-0.02%)
UNH : 340.51 (-1.01%)
ELV : 374.97 (+0.57%)
PFE : 25.27 (-0.82%)
TSLA : 448.96 (+0.89%)
LLY : 1,081.00 (+1.64%)
Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without bevacizumab...

PFE : 25.27 (-0.82%)
Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On

There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at 210.16. In the money by 12.8%, it sets up for a couple of different trading...

GOOG : 332.73 (+1.09%)
PFE : 25.27 (-0.82%)
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025

DGX : 175.94 (+0.86%)
EXAS : 102.23 (+0.12%)
ILMN : 145.55 (+3.18%)
ARVN : 12.15 (+0.66%)
PFE : 25.27 (-0.82%)
QTRX : 7.36 (-8.68%)
Worried About a K-Shaped Economy? Buy This Top Dividend ETF for 2026.

SCHD looks well-positioned to outperform significantly if the economy turns south in 2026.

LMT : 551.24 (+1.53%)
KO : 70.50 (-0.01%)
SCHD : 28.50 (-0.18%)
PEP : 141.36 (+1.04%)
ABBV : 220.04 (-0.02%)
AMGN : 325.54 (-0.17%)
PFE : 25.27 (-0.82%)
BMY : 55.77 (-0.16%)
Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio

- Number of Lawsuits Increases Fivefold to Over 2,100 Since May - FDA Approves Brain Tumour Warning Global pharmaceutical company...

RKT.LN : 6,228.000 (+0.84%)
JNJ : 209.72 (+2.61%)
PFE : 25.27 (-0.82%)
Pfizer's Quarterly Earnings Preview: What You Need to Know

Pfizer will release its fourth-quarter earnings next month, and analysts anticipate a low double-digit profit dip.

XLV : 157.38 (+0.04%)
$SPX : 6,977.27 (+0.16%)
PFE : 25.27 (-0.82%)
2 S&P 500 Stocks with Competitive Advantages and 1 We Avoid

2 S&P 500 Stocks with Competitive Advantages and 1 We Avoid

ROST : 192.26 (+0.43%)
PFE : 25.27 (-0.82%)
AJG : 264.84 (+0.09%)
Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

JNJ : 209.72 (+2.61%)
LLY : 1,081.00 (+1.64%)
ABBV : 220.04 (-0.02%)
GSK : 50.39 (unch)
CSLLY : 58.7700 (+0.41%)
PFE : 25.27 (-0.82%)
SNY : 47.60 (-2.92%)
These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever

With the S&P 500 trading at 26 times forward earnings, valuations are a concern entering 2026. Consider these 3 discounted stocks to insulate your portfolio.

NVDA : 184.94 (+0.04%)
GOOGL : 331.86 (+1.00%)
CMCSA : 29.06 (+2.43%)
T : 23.74 (+0.12%)
MU : 345.87 (+0.23%)
LLY : 1,081.00 (+1.64%)
PFE : 25.27 (-0.82%)
DIS : 112.82 (-2.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 26.36
2nd Resistance Point 26.06
1st Resistance Point 25.67
Last Price 25.27
1st Support Level 24.98
2nd Support Level 24.68
3rd Support Level 24.29

See More

52-Week High 27.69
Last Price 25.27
Fibonacci 61.8% 25.10
Fibonacci 50% 24.30
Fibonacci 38.2% 23.50
52-Week Low 20.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar